Dual antiplatelet therapy

Phase 3Small molecule

SSeoul St. Mary's Hospital

Dual antiplatelet therapy is one of 72 small molecule programs targeting Stroke, Acute. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stroke, AcuteRecruiting

Acute Myocardial InfarctionActive, not recruiting

AneurysmActive, not recruiting

Coronary Heart DiseaseRecruiting

Stroke, AcutePhase 3

Recruiting

Acute Myocardial InfarctionPreclinical

Active, not recruiting

AneurysmPreclinical

Active, not recruiting

Coronary Heart DiseasePreclinical

Recruiting

Competition

Competitive Landscape

75 competitors in Acute Myocardial Infarction

#DrugCompanyPhaseTrials

Plavix

Sanofi

Approved

6 2

Bayer Aspirin

Bayer

Approved

2 3

Praluent

Regeneron

Approved

1 4

Avapro

Sanofi

Approved

1 5

Zebeta

Teva

Approved

1 6

Radicava

Shionogi

Approved

1 7

Onglyza

Neoral

Angiomax

BBaxter Healthcare Corporation

Approved

3 10

Zetia

OOrganon and Co

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalRecruiting

Percutaneous Coronary Intervention

NCT06916520

Post-ApprovalRecruiting

Stroke

NCT07095790

Q1 2028

N/ARecruiting

Dual Antiplatelet Therapy

NCT06535568

Q2 2028

Post-ApprovalNot yet recruiting

Rivaroxaban

NCT07195812

Q2 2029

Phase 3Recruiting

Stroke, Acute

NCT07379190

Clinical

Trials by Indication[1]

Antithrombotic1 trial

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

Recruiting·MMcMaster University··NCT05646394·150 enrolled

Active, not recruiting·YYonsei University·Phase 4·NCT03947229·3,200 enrolled

Rivaroxaban1 trial

Rivaroxaban for Slow Coronary Flow After PCI in STEMI

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT07195812·60 enrolled

10 more indications

Percutaneous Coronary Intervention1 trial

Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)

Recruiting·JJ.P.S Henriques·Phase 4·NCT06916520·300 enrolled

Stroke1 trial

Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke

Recruiting·SSecond Affiliated Hospital of Soochow University·Phase 4·NCT07095790·580 enrolled

STEMI1 trial

EROSION II: OCT Guided PPCI in STEMI

Unknown status·HHarbin Medical University··NCT03062826·347 enrolled

Acute Myocardial Infarction1 trial

CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)

Unknown status·SSeoul St. Mary's Hospital··NCT02806102·13,000 enrolled

Coronary Artery Bypass1 trial

Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting

Completed·CChina National Center for Cardiovascular Diseases·Phase 4·NCT05380063·2,300 enrolled

AIN1 trial

Xience Versus Synergy in Left Main PCI

Unknown status·NNHS National Waiting Times Centre Board·N/A·NCT02303717·818 enrolled

Coronary Heart Disease1 trial

An Investigator-initiated, Multicenter, Open-label, Randomized Controlled Non-inferiority Trial to Assess the Single vs. Dual Antiplatelet Therapy in the Chronic Coronary Syndrome (CCS) and Stable Acute Coronary Syndrome (S-ACS) Patients Undergoing Percutaneous Intervention With Drug-coated Balloons (DCB)-Only Strategy (KONG-FREEDOM-I)

Recruiting·GGan Lijun·Preclinical·NCT07587099·2,170 enrolled

Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)1 trial

Aspirin-Free Strategy After 3-6 Month Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Who Underwent Complete Revascularization : A Randomized Controlled Trial

Not yet recruiting·AAssiut University·Approved·NCT07736196·300 enrolled

Stroke, Acute1 trial

Efficacy and Safety of Tirofiban Therapy in Acute Ischemic Stroke Patients Beyond the Time Window Guided by High-Resolution Magnetic Resonance Imaging

Recruiting·WWeifang Medical University·Phase 3·NCT07379190·458 enrolled

Unspecified1 trial

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

Terminated·HHonorHealth Research Institute·Phase 2·NCT03606642·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Dual antiplatelet therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dual antiplatelet therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dual antiplatelet therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul St. Mary's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSeoul St. Mary's Hospital

Dual antiplatelet therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Q2 2028

Q2 2029

Trials by Indication[1]

Antithrombotic1 trial

Aneurysm1 trial